Literature DB >> 15933596

Perfluorohexylethan (O62) as ocular endotamponade in complex vitreoretinal surgery.

Hans Hoerauf1, Johann Roider, Karin Kobuch, Horst Laqua.   

Abstract

PURPOSE: To investigate the safety and performance of perfluorohexylethan (O62), a partially fluorinated alkane, as an intraoperative tool and heavy ocular endotamponade in complex vitreoretinal surgery. PATIENTS AND METHODS: In a prospective clinical study, O62 was used as a postoperative ocular endotamponade in 11 eyes of 11 patients after pars plana vitrectomy for the following inferior pathologic conditions, proliferative vitreoretinopathy (n = 8), rhegmatogenous retinal redetachment with inferior tears (n = 1), and inferior giant tear (n = 2). The median duration of the O62 tamponade was 43 days (range, 17-55 days), and the median follow-up period after removal of the tamponade was 16 months.
RESULTS: The initial postoperative retinal attachment rate was 100%. In 7 of 11 eyes, the retina remained attached during the O62 tamponade and after its removal. During the tamponade period, no epiretinal membrane formation or macular pucker was observed in these seven eyes. Recurrent retinal detachments with proliferative vitreoretinopathy developed in 4 of 11 eyes under the tamponade. The median follow-up after removal of O62 was 16 months. A secondary cataract developed in all five phakic eyes. Severe emulsification was noted in all patients starting in the second week after surgery causing a decrease of visual acuity and a significantly reduced funduscopic view. In the early postoperative period, a marked inflammatory reaction in the anterior segment was seen in all patients. Slightly whitish precipitates were noted in 2 of 11 eyes. A transient increase in intraocular pressure up to 35 mmHg was observed in 2 of 11 eyes.
CONCLUSION: O62 showed good tamponade properties for the inferior retina over 6 weeks. However, its use as a postoperative retinal tamponade is limited by its severe emulsification propensity and unclear inflammatory potential.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15933596     DOI: 10.1097/00006982-200506000-00014

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Primary vitrectomy with Densiron-68 for rhegmatogenous retinal detachment.

Authors:  M R Romano; T Stappler; J Marticorena; C Groenewald; I Pearce; S K Gibran; D Wong; H Heimann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-07-11       Impact factor: 3.117

Review 2.  [Current importance of heavy fluids as intraoperative aids in vitreoretinal surgery].

Authors:  Nicolas Feltgen; Hans Hoerauf
Journal:  Ophthalmologe       Date:  2019-10       Impact factor: 1.059

3.  Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy.

Authors:  Stephen G Schwartz; Harry W Flynn; Xue Wang; Ajay E Kuriyan; Samuel A Abariga; Wen-Hsiang Lee
Journal:  Cochrane Database Syst Rev       Date:  2020-05-13

Review 4.  The concept of heavy tamponades-chances and limitations.

Authors:  Antonia M Joussen; David Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-11       Impact factor: 3.117

Review 5.  Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy.

Authors:  Stephen G Schwartz; Harry W Flynn; Wen-Hsiang Lee; Elizabeth Ssemanda; Ann-Margret Ervin
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

Review 6.  Tamponade in surgery for retinal detachment associated with proliferative vitreoretinopathy.

Authors:  Stephen G Schwartz; Harry W Flynn; Wen-Hsiang Lee; Xue Wang
Journal:  Cochrane Database Syst Rev       Date:  2014-02-14

Review 7.  Heavy silicone oil and intraocular inflammation.

Authors:  Francesco Morescalchi; Ciro Costagliola; Sarah Duse; Elena Gambicorti; Barbara Parolini; Barbara Arcidiacono; Mario R Romano; Francesco Semeraro
Journal:  Biomed Res Int       Date:  2014-07-08       Impact factor: 3.411

8.  Anatomical success rate of pars plana vitrectomy for treatment of complex rhegmatogenous retinal detachment.

Authors:  Xhevat Lumi; Zala Lužnik; Goran Petrovski; Beáta Éva Petrovski; Marko Hawlina
Journal:  BMC Ophthalmol       Date:  2016-12-09       Impact factor: 2.209

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.